Recent Quotes
My Watchlist
Indicators
Local Stocks
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se Ads (NQ: ARGX )

310.98 USD -4.31 (-1.37%)
Official Closing Price Updated: 4:40 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Argenx Se Ads

< Previous 1 2 Next >
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology
--- argenx gains access to ENHANZE® subcutaneous delivery technology for up to three targets, including exclusive rights to develop therapeutic products targeting human neonatal Fc receptor FcRn --- 
From PR Newswire
argenx and Halozyme enter global collaboration and license agreement for ENHANZE® technology
From GlobeNewswire News Releases
Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia
Forbion Portfolio Company Staten Biotechnology Enters into a Collaboration with Novo Nordisk to Develop Novel Treatment for Dyslipidaemia 
From Business Wire News Releases
argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia
From GlobeNewswire News Releases
argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)
From GlobeNewswire News Releases
argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition
From GlobeNewswire News Releases
argenx reports third quarter 2018 financial results and provides business update
From GlobeNewswire News Releases
argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology
From GlobeNewswire News Releases
argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody
From GlobeNewswire News Releases
argenx to Present at 2018 Wedbush PacGrow Healthcare Conference
From GlobeNewswire News Releases
argenx receives second preclinical milestone payment under its development agreement with AbbVie
From GlobeNewswire News Releases
iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director
From GlobeNewswire News Releases
argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris
From GlobeNewswire News Releases
argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation
From GlobeNewswire News Releases
argenx selected for BEL 20 Index
From GlobeNewswire News Releases
argenx reports first quarter 2018 financial results and provides business update
From GlobeNewswire News Releases
argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in generalized myasthenia gravis at American Academy of Neurology (AAN) Annual Meeting
From GlobeNewswire News Releases
argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112
From GlobeNewswire News Releases
argenx appoints Keith Woods as Chief Operating Officer
From GlobeNewswire News Releases
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe
From GlobeNewswire News Releases
argenx reports fourth quarter business update and full year 2017 financial results
From GlobeNewswire News Releases
argenx announces closing of U.S. public offering for gross proceeds of approximately $266 million
From GlobeNewswire News Releases
argenx raises approximately $231 million in gross proceeds in an upsized U.S. public offering
From GlobeNewswire News Releases
argenx announces launch of proposed public offering in the United States
From GlobeNewswire News Releases
argenx to provide updates on Phase 1/2 clinical trials of ARGX-110 in Acute Myeloid Leukemia and Cutaneous T-Cell Lymphoma during American Society of Hematology Annual Meeting
From GlobeNewswire News Releases
argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis
From GlobeNewswire News Releases
argenx to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
argenx announces results of extraordinary shareholders' meeting 2017
From GlobeNewswire News Releases
argenx to host KOL breakfast symposium on pemphigus vulgaris on November 10, 2017
From GlobeNewswire News Releases
argenx launches Phase I trial with subcutaneous formulation of ARGX-113
From GlobeNewswire News Releases
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.